Treatment of failing arterio-venous dialysis graft by angioplasty, stent, and stent graft: Two-years analysis of patency rates and cost-effectiveness
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F19%3A10402414" target="_blank" >RIV/00064165:_____/19:10402414 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/19:10402414
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=CRNLXt_2H7" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=CRNLXt_2H7</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3892/etm.2019.8050" target="_blank" >10.3892/etm.2019.8050</a>
Alternative languages
Result language
angličtina
Original language name
Treatment of failing arterio-venous dialysis graft by angioplasty, stent, and stent graft: Two-years analysis of patency rates and cost-effectiveness
Original language description
The objective of this prospective randomized single-center study was to compare primary and secondary patency rates, number of percutaneous transluminal angioplasty (PTA) interventions and cost-effectiveness among PTA, deployment of a stent, or a stent graft in the treatment of failing arteriovenous dialysis grafts (AVG) due to restenosis in the venous anastomosis or the outflow vein. Altogether 60 patients with failing AVG and restenosis in the venous anastomosis or the outflow vein were randomly assigned to either PTA, placement of a stent (E-Luminexx (R)) or stent graft (Fluency Plus (R)). After the procedure, patients with stent or stent graft received dual antiplatelet therapy for the next three months. Follow-up angiography was scheduled at 3, 6, and 12 months unless requested earlier due to suspected stenosis or malfunction of the access. Subsequently, angiography was performed only if requested by the clinician. During a median follow-up of 22.4 (IQR=5.7) months patients with PTA, stent, or stent graft required 3.1 +/- 1.7, 2.5 +/- 1.7, or 1.7 +/- 2.1 (P=0.031) secondary PTA interventions. The primary patency rates were 0, 18 and 65% at 12 months and 0, 18 and 37% at 24 months in the PTA, stent, and stent graft group respectively (P<0.0001). The cost of the procedures in the first two years was (sic)7,900 +/-(sic)3,300 in the PTA group, (sic)8,500 +/-(sic)4,500 in the stent group, and (sic)7,500 +/-(sic)6,200 in the stent graft group (P=0.45). We conclude that the treatment of failing dialysis vascular access by the deployment of a stent graft significantly improves its primary patency rates and decreases the number of secondary PTA interventions; however, the reduction in costs for maintaining AVG patency is not significant.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems
Result continuities
Project
<a href="/en/project/NT14160" target="_blank" >NT14160: Restenoses of dialysis vascular access: quantification, understanding the etiology and the effectiveness of modern percutaneous therapy</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Experimental and Therapeutic Medicine
ISSN
1792-0981
e-ISSN
—
Volume of the periodical
18
Issue of the periodical within the volume
5
Country of publishing house
GR - GREECE
Number of pages
7
Pages from-to
4144-4150
UT code for WoS article
000503217400108
EID of the result in the Scopus database
—